Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Relatlimab and Nivolumab in Advanced Melanoma - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Drug: Relatlimab and Nivolumab in Advanced Melanoma

New Drug: Relatlimab and Nivolumab in Advanced Melanoma
  • Double-blind, randomized Phase II-III trial
  • Untreated metastatic or unresectable melanoma
  • Relatlimab and nivolumab vs nivolumab alone
  • mPFS: 10.1 vs 4.6 mos (HR:0.75; P=0.006)
  • 12 months PFS: 47.7% vs 36.0%
  • PD L1<1 mPFS: 6.4 vs 2.9 mos (HR:0.66)
  • PD L1>=1 mPFS: 15.7 vs 14.7 mos (HR:0.95)
  • Most AE’s: Hypothyroidism or thyroiditis (in 18.0% of the patients), rash (in 9.3%), diarrhea or colitis (in 6.8%) in combination arm
  • Grade >=3 increased levels of lipase (1.7%), ALT (1.4%), AST (1.4%), fatigue (1.1%) in combination arm

N Engl J Med. 2022 Jan 6;386(1):24-34.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma


Reviewed by Hasan Cagri Yildirim, MD on Mar 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More